Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies

Table 2 Toxicity incidence

Toxicity	n1(%)
Post-embolization syndrome2	11 (12.79)
Constitutional toxicities2	48 (55.81)
Fatigue	41 (47.67)
Loss of appetite	15 (17.44)
Weakness	11 (12.79)
Fever	6 (6.98)
Weight loss	5 (5.81)
Flu-like symptoms	5 (5.81)
Malaise	4 (4.65)
Chills	2 (2.33)
Gastrointestinal toxicities2	47 (55.29)
Abdominal pain	34 (40.00)
Nausea	23 (27.06)
Emesis	10 (11.76)
Constipation	6 (7.06)
Diarrhea	3 (3.53)
Abdominal Cramps	1 (1.18)
Hepatic toxicities2	38 (44.19)
Alkaline phosphatase	27 (34.18)
Albumin	21 (26.58)
Total bilirubin	18 (22.78)
Aspartate aminotransferase	9 (11.39)
INR	3 (4.29)
Encephalopathy	2 (2.33)
Jaundice	2 (2.33)
Ascites	1 (1.16)

¹n for this Table was determined based on the number of the original 104 patients included in our study with clinical or laboratory follow-up. There were 86 patients with clinical follow-up but only 79 patients with laboratory follow-up, 9 of whom did not have post-treatment INR values obtained;

²High incidence of toxicity. INR: International normalized ratio.